Revelation Biosciences (REVB) Registration filing summary

Company overview and business model

• Clinical-stage life science company focused on rebalancing inflammation using proprietary Gemini formulation targeting acute kidney injury (AKI), chronic kidney disease (CKD), post-surgical infection (PSI), and post-burn infection (PBI).

• Pipeline includes multiple programs based on Gemini, a synthetic TLR4 agonist designed to modulate immune response.

• Incorporated in Delaware in 2019, headquartered in San Diego, CA.

Financial performance and metrics

• As of March 31, 2025: $3.7M in cash and cash equivalents, $2.9M in stockholders' equity, and $42.6M accumulated deficit.

• Net loss of $15.0M for the year ended December 31, 2024, and $2.1M for the three months ended March 31, 2025.

• No revenue generated to date; expects continued operating losses and negative cash flows for the foreseeable future.

Use of proceeds and capital allocation

• Estimated net proceeds of $4.3M from the offering (assuming $2.565 per share), to be used for ongoing Phase 1b clinical study completion, manufacturing clinical drug supply, additional preclinical work, further product development, and general corporate purposes.

• Proceeds are not sufficient to fund product candidates through regulatory approval; additional capital will be required.